Pharmacokinetic Properties of 2nd-Generation Fibroblast Growth Factor-1 Mutants for Therapeutic Application

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Xia, Xue ^a   Babcock, Joseph P ^a   Blaber, Sachiko I ^a   Harper, Kathleen M ^a   Blaber, Michael ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FIBROBLAST GROWTH FACTOR 1; GLUCOSE; HEPARIN; PROTEOHEPARAN SULFATE; TRIACYLGLYCEROL; RECOMBINANT PROTEIN; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; EXPERIMENTAL RABBIT; GLUCOSE BLOOD LEVEL; ISCHEMIA; MALE; MEAN RESIDENCE TIME; MUTATIONAL ANALYSIS; NONHUMAN; POINT MUTATION; SENSITIVITY ANALYSIS; STRUCTURE ANALYSIS; THERMOSTABILITY; TRIACYLGLYCEROL BLOOD LEVEL; VASCULARIZATION; ANIMAL; CHEMISTRY; ESCHERICHIA COLI; GENETICS; HUMAN; KINETICS; METABOLISM; MUTATION; PROTEIN CONFORMATION; RABBIT;

ORYCTOLAGUS CUNICULUS;

ANIMALS; BLOOD GLUCOSE; ESCHERICHIA COLI; FIBROBLAST GROWTH FACTOR 1; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; ISCHEMIA; KINETICS; MALE; MUTATION; PROTEIN CONFORMATION; RABBITS; RECOMBINANT PROTEINS; SULFHYDRYL COMPOUNDS; TRIGLYCERIDES;

EID: 84868326394     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048210     Document Type: Article

References (64)

1. Levi-Montalcini R, (1964) The Nerve Growth Factor. Annals of the New York Academy of Sciences 118: 149-170.
2. Hoober JK, Cohen S, (1967) Epidermal growth factor. 1. The stimulation of protein and ribonucleic acid synthesis in chick embryo epidermis. Biochimica et Biophysica Acta 138: 347-356.
3. Schenkein I, Levy M, Bueker ED, Tokarsky E, (1968) Nerve growth factor of very high yield and specific activity. Science 159: 640-643.
4. Rudland PS, Seifert W, Gospodarowicz D, (1974) Growth control in cultured mouse fibroblasts: induction of the pleiotypic and mitogenic responses by a purifed growth factor. Proc Natl Acad Sci U S A 71: 2600-2604.
5. Schumacher B, Stegmann T, Pecher P, (1998) The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: first clinical results. J Cardiovasc Surg (Torino) 39: 783-789.
6. Stegmann TJ, Hoppert T, Schlurmann W, Gemeinhardt S, (2000) First angiogenic treatment of coronary heart disease by FGF-1: long-term results after 3 years. Cardiac and Vascular Regeneration 1: 5-9.
7. Wagoner L, Merrill W, Jacobs J, Conway G, Boehmer J, et al. (2007) Angiogenesis protein therapy with human fibroblast growth factor (FGF-1): results of a phase I open label, dose escalation study in subjects with CAD not eligible for PCI or CABG. Circulation 116suppl. II: 443.
8. Ioli V, Wiens B, Mellin T, Thomas K, Ellis R, et al. (1992) Effect of Topically Applied Acidic Fibroblast Growth Factor (FGF-1) on Healing of Chronic Venous Stasis and Diabetic Ulcers. Abstracts of the 5th Annual Symposium on Advanced Wound Care: 150.
9. Mellin TN, Mennie RJ, Cashen DE, Ronan JJ, Capparella J, et al. (1992) Acidic fibroblast growth factor accelerates dermal wound healing. Growth Factors 7: 1-14.
10. Mellin TN, Cashen DE, Ronan JJ, Murphy BS, DiSalvo J, et al. (1995) Acidic fibroblast growth factor accelerates dermal wound healing in diabetic mice. Journal of Investigative Dermatology 104: 850-855.
11. Bing M, Da-Sheng C, Zhao-Fan X, Dao-Feng B, Wei L, et al. (2007) Randomized, multicenter, double-blind, and placebo-controlled trial using topical recombinant human acidic fibroblast growth factor for deep partial-thickness burns and skin graft donor site. Wound Repair and Regeneration 15: 795-799.
12. Wang W, Lin S, Xiao Y, Huang Y, Tan Y, et al. (2008) Acceleration of diabetic wound healing with chitosan-crosslinked collagen sponge containing recombinant human acidic fibroblast growth factor in healing-impaired STZ diabetic rats. Life Sciences 82: 190-204.
13. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, et al. (1998) Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98: 2800-2804.
14. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, et al. (1999) Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100: 468-474.
15. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, et al. (2003) Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107: 2677-2683.
16. Schumacher B, Pecher P, von Specht BU, Stegmann T, (1998) Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clincal results of a new treatment of coronary heart disease. Circulation 97: 645-650.
17. Landau C, Jacobs AK, Haudenschild CC, (1995) Intrapericardial basic fibroblast growth factor induces myocardial angiogenesis in a rabbit model of chronic ischemia. American Heart Journal 129: 924-931.
18. Laham RJ, Rezaee M, Post M, Novicki D, Sellke FW, et al. (2000) Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. J Pharmacol Exp Ther 292: 795-802.
19. Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A, (1991) Role of platelet-derived growth factor in wound healing. J Cell Biochem 45: 319-326.
20. Brown RL, Breeden MP, Greenhalgh DG, (1994) PDGF and TGF-a act synergistically to improve wound healing in the genetically diabetic mouse. J Surg Res 56: 562-570.
21. Jimenez PA, Rampy MA, (1999) Keratinocyte growth factor-2 accelerates wound healing in incisional wounds. J Surg Res 81: 238-242.
22. Marti GP, Mohebi P, Liu L, Wang J, Miyashita T, et al. (2008) KGF-1 for wound healing in animal models. Methods Mol Biol 423: 383-391.
23. Blaber SI, Culajay JF, Khurana A, Blaber M, (1999) Reversible thermal denaturation of human FGF-1 induced by low concentrations of guanidine hydrochloride. Biophysical Journal 77: 470-477.
24. Copeland RA, Ji H, Halfpenny AJ, Williams RW, Thompson KC, et al. (1991) The structure of human acidic fibroblast growth factor and its interaction with heparin. Archives of Biochemistry and Biophysics 289: 53-61.
25. Alsenaidy MA, Wang T, Kim JH, Joshi SB, Lee J, et al. (2012) An empirical phase diagram approach to investigate conformational stability of "second-generation" functional mutants of acidic fibroblast growth factor (FGF-1). Protein Sci 21: 418-432.
26. Seitz CS, Brocker EB, Trautman A, (2008) Management of allergy to heparins in postoperative care: subcutaneous allergy and intravenous tolerance. Dermatology 14: 4.
27. Prechel M, Walenga JM, (2012) Heparin-induced thrombocytopenia: an update. Seminars in Thrombostasis and Hemostasis 38: 483-496.
28. Matuszewska B, Keogan M, Fisher DM, Soper KA, Hoe C-M, et al. (1994) Acidic fibroblast growth factor: evaluation of topical formulations in a diabetic mouse wound healing model. Pharmaceutical Research 11: 65-71.
29. Kurtzman AL, Govindarajan S, Vahle K, Jones JT, Heinrichs v, et al. (2001) Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins. Curr Opin Biotech 12: 361-370.
30. Dubey VK, Lee J, Somasundaram T, Blaber S, Blaber M, (2007) Spackling the crack: stabilizing human fibroblast growth factor-1 by targeting the N and C terminus beta-strand interactions. J Mol Biol 371: 256-268.
31. Lee J, Blaber M, (2009) The interaction between thermostability and buried free cysteines in regulating the functional half-life of fibroblast growth factor-1. Journal of Molecular Biology 393: 113-127.
32. Brych SR, Dubey VK, Bienkiewicz E, Lee J, Logan TM, et al. (2004) Symmetric primary and tertiary structure mutations within a symmetric superfold: a solution, not a constraint, to achieve a foldable polypeptide. J Mol Biol 344: 769-780.
33. Brych SR, Blaber SI, Logan TM, Blaber M, (2001) Structure and stability effects of mutations designed to increase the primary sequence symmetry within the core region of a β-trefoil. Protein Science 10: 2587-2599.
34. Brych SR, Kim J, Logan TM, Blaber M, (2003) Accommodation of a highly symmetric core within a symmetric protein superfold. Protein Science 12: 2704-2718.
35. McLachlan AD, (1979) Three-fold structural pattern in the soybean trypsin inhibitor (Kunitz). Journal of Molecular Biology 133: 557-563.
36. Murzin AG, Lesk AM, Chothia C, (1992) β-Trefoil fold. Patterns of structure and sequence in the kunitz inhibitors interleukins-1β and 1α and fibroblast growth factors. Journal of Molecular Biology 223: 531-543.
37. Beadle BM, Shoichet BK, (2002) Structural basis of stability- function tradeoffs in enzymes. Journal of Molecular Biology 321: 285-296.
38. Tokuriki N, Stricher F, Serrano L, Tawfik DS, (2008) How protein stability and new functions trade off. PLoS Comput Biol 4: e1000002.
39. Gimenez-Gallego G, Conn G, Hatcher VB, Thomas KA, (1986) The complete amino acid sequence of human brain-derived acidic fibroblast growth factor. Biochemical and Biophysical Research Communications 128: 611-617.
40. Tsai PK, Volkin DB, Dabora JM, Thompson KC, Bruner MW, et al. (1993) Formulation design of acidic fibroblast growth factor. Pharmaceutical Research 10: 649-659.
41. Zazo M, Lozano RM, Ortega S, Varela J, Diaz-Orejas R, et al. (1992) High-level synthesis in Escherichia coli of a shortened and full-length human acidic fibroblast growth factor and purification in a form stable in aqueous solutions. Gene 113: 231-238.
42. Gill SC, von Hippel PH, (1989) Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem 182: 319-326.
43. Little RA, (1969) Local and general responses to injury in the newborn rabbit. Postgrad Med J 45: 559-561.
44. Baffour R, Berman J, Garb JL, Rhee SW, Kaufman J, et al. (1992) Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. Journal of Vascular Surgery 16: 181-192.
45. Pu L-Q, Sniderman AD, Brassard R, Lachapelle KJ, Graham AM, et al. (1993) Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation 88: 208-215.
46. Pu L-Q, Jackson S, Lachapelle KJ, Arekat Z, Graham AM, et al. (1994) A persistent hindlimb ischemia model in rabbit. Journal of Investigative Surgery 7: 49-60.
47. Rosenbaum S (2011) Basic pharmacokinetics and pharmacodynamics- an integrated textbook and computer simulations. Hoboken: John Wiley & Sons, Inc.
48. Hgashiyama A, Watkins MW, Chen Z, LeWinter MM, (1995) Effects of EMD 57033 on Contraction and Relaxation in Isolated Rabbit Hearts. Circulation 92: 3094-3104.
49. Preckel B, Schlack W, Heibel T, Rutten H, (2002) Xenon produces minimal haemodynamic effects in rabbits with chronically compromised left ventricular function. British Journal of Anaesthesia 88: 264-269.
50. Evans GO, editor (2009) Animal clinical chemistry- a practical handbook for toxicologists and biomedical researchers. Boca Raton: Taylor & Francis Group LLC.
51. Thrall MA, Baker DC, Campbell TW, DeNicola DB, Fettman MJ, et al. (2004) Veterinary hematology and clinical chemistry. Hoboken: Wiley Blackwell Publishing.
52. Willard MD, Tvedten H (2007) Small animal clinical diagnosis by laboratory methods. Philadelphia: W.B. Saunders Co.
53. Rosengart TK, Kuperschmid JP, Maciag T, Clark RE, (1989) Pharmacokinetics and distribution of heparin-binding growth factor-1 (endothelial cell growth factor) in the rat. Circulation Research 64: 227-234.
54. Hondermarck H, Courty J, Boilly B, Thomas D, (1990) Distribution of intravenously administered acidic and basic fibroblast growth factors in mouse. Experientia 46: 973-974.
55. Zinn KR, Kelpke S, Chaudhuri TR, Sugg T, Mountz JM, et al. (2000) Imaging Tc-99m-labeled FGF-1 targeting in rats. Nuclear Medicine & Biology 27: 407-414.
56. Hacker U, Nybakken K, Perrimon N, (2005) Heparan sulphate proteoglycans: the sweet side of development. Nature Rev 6: 530-541.
57. Beenken A, Mohammadi M, (2009) The FGF family: biology, pathophysiology and therapy. Nature Rev 8: 235-253.
58. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, et al. (2004) Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145: 2594-2603.
59. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, et al. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-1635.
60. Ryden M, (2009) Fibroblast growth factor 21: an overview from a clinical perspective. Cell Mol Life Sci 66: 2067-2073.
61. Reiche M, Bachmann A, Lossner U, Bluher M, Stumvoll M, et al. (2010) Fibroblast growth factor 19 serum levels: relation to renal function and metabolic parameters. Horm Metab Res 42: 178-181.
62. Blaber M, DiSalvo J, Thomas KA, (1996) X-ray crystal structure of human acidic fibroblast growth factor. Biochemistry 35: 2086-2094.
63. Lee J, Blaber SI, Dubey VK, Blaber M, (2011) A polypeptide "building block" for the ß-trefoil fold identified by "top-down symmetric deconstruction". J Mol Biol 407: 744-763.
64. Hewitt CD, Innes DJ, Savory J, Wills MR, (1989) Normal biochemical and hematological values in New Zealand White rabbits. Clinical Chemistry 35: 1777-1779.